[Clinical-electrophysiologic studies on the actions of the anti-arrhythmic substance AWD-G256 in man].

Abstract

The effects of the new antiarrhythmic drug AWD-G256 (1) were investigated by clinical electrophysiology (His bundle electrography, programmed electrical stimulation) in 19 patients with supraventricular tachycardias but without structural heart disease. In a maximal dosage of 0.45 mg/kg body mass 1 only minimally affects electrophysiological parameters of the impulse formation and conduction. At this time the therapeutic value of 1 is not clear.

• Authors: H Volkmann, A Hoffmann, H Kühnert, G Dannberg, M Heinke, I Reimann, J P Marschner, K Farker
• Journal: Die Pharmazie (Pharmazie) Vol. 48 Issue 5 Pg. 380-5 (May 1993) ISSN: 0031-7144 [Print] Germany
• Vernacular Title: Klinisch-elektrophysiologische Untersuchungzen zur Wirkung der antiarrhythmischen Substanz AWD-G256 beim Menschen.
• PMID: 8327568 (Publication Type: English Abstract, Journal Article)

Chemical References

• Anti-Arrhythmia Agents
• Benzophenones
• Hydrazones
• (Z)-2-amino-5-chlorobenzophenonamidinohydrazone acetate

Topics

• Adult
• Anti-Arrhythmia Agents (pharmacology, therapeutic use)
• Benzophenones (pharmacology, therapeutic use)
• Bundle of His (drug effects, physiology)
• Electric Stimulation
• Electrophysiology
• Heart Conduction System (drug effects)
• Hemodynamics (drug effects)
• Humans
• Hydrazones (pharmacology, therapeutic use)
• Male
• Middle Aged
• Purkinje Cells (drug effects)
• Sinoatrial Node (drug effects)
• Tachycardia, Supraventricular (drug therapy, physiopathology)